TyraTech, Inc. Directorate Change (2161V)
10 January 2013 - 6:00PM
UK Regulatory
TIDMTYR TIDMTYRU
RNS Number : 2161V
TyraTech, Inc.
10 January 2013
10 January 2013
TyraTech, Inc.
("Tyratech" or the "Company")
Directorate Change
Appointment of experienced life science CEO as part of
commercialisation phase
The Board of TyraTech (AIM: TYR and TYRU), a life sciences
company focusing on natural pest control and healthcare products,
is pleased to announce the appointment of Bruno Jactel, 51, as
Chief Executive Officer with immediate effect. Mr Jactel joins the
Executive Board as the Company accelerates its transition toward
commercialisation.
Mr. Jactel spent 12 years at Merial Limited ("Merial"), the
US$2.6 billion revenue generating Animal Health subsidiary of the
Sanofi Group, most recently as combined Chief Strategy Officer and
Chief Marketing Officer. As Head of commercial operations in
Europe, Mr. Jactel developed successful growth strategies in both
OTC and professional channels. He was further responsible for
global marketing, brand management and enterprise and franchise
strategy, in addition to being a co-chair on the R&D steering
committee. During this time, Merial built the most successful
consumer brand in animal health history with FRONTLINE (Flea and
tick product for pets) reaching $1b in annual revenue in 2009.
Prior to working at Merial, Mr. Jactel was Deputy Minister for
Economic and Commercial Affairs at the French Embassy in Washington
D.C. He is also a recent founder and board member of Hypercell
Technologies LLC, an early-stage biotech company developing
therapeutic solutions to serious infectious animal disease. Mr.
Jactel is a Doctor of Veterinary Medicine and has a Masters in
Economic Sciences from the Sorbonne University in Paris. He
graduated from the Ecole Nationale d'Administration, Paris in
1993.
To ensure a smooth transition, Alan Reade will remain as
Executive Chairman until at least the end of the first quarter of
2013. Alan will then revert to the role of Non-Executive Chairman
and in that capacity will continue to support the Company both as a
Board Member and an investor.
Alan Reade, Executive Chairman of TyraTech, commented: "Bruno
joins at a pivotal time in the Company's history and his
appointment will enhance the commercial competencies of TyraTech as
well as bringing a new dynamic to an already strong Board.
"From my time as Executive Chairman of Merial I know that
Bruno's marketing, scientific background, business skills and
experience make him the ideal person to lead TyraTech moving
forward. The Company is focused on realising the significant
commercial opportunities in the Personal Care, Animal Health and
Consumer markets, where products are either ready for market or in
the final stages of development. In addition, we continue to
support our recently announced joint venture with Amvac Chemical
Corporation, another exciting development for TyraTech."
Bruno Jactel, Chief Executive Officer, commented: "TyraTech has
a powerful combination of natural branded products, strong research
and operational teams, a first rate technology platform and a
commercial and technical network that ideally positions the Company
for future commercialisation. I am looking forward to working with
the team and leading TyraTech into the next phase of its
development."
Further information about Bruno Jactel:
Bruno Georges Jactel
Directorships and partnerships held over the five years
preceding the date of appointment are as follows:
Current:
Hypercell Technologies LLC
Past:
Nil
There are no further disclosures required under Schedule 2(g) of
the AIM rules for Companies.
Mr. Jactel is interested in 419,050 common shares representing
an interest of 0.39 per cent of the total voting rights of the
Company.
For further information please contact:
TyraTech Inc.
Alan Reade, Executive Chairman
Tel: +1 919 415 4310
Peter Jerome, Chief Financial Officer
Tel: +1 919 415 4280
N+1 Singer, Nominated Adviser and Joint Broker
Aubrey Powell / Alex Wright
Tel: +44 20 7496 3000
First Columbus LLP, Joint Broker
Chris Crawford
Tel: +44 20 3002 2070
Walbrook, Financial PR and IR
Bob Huxford /Helen Westaway (Public Relations)
Tel + 44 7933 8792
Paul Cornelius (Investor Relations)
Tel +44 20 7933 8794
Notes to Editors:
TyraTech, Inc. was established in 2004 to utilize its novel
technology to fill the unmet and increasing global demand for
effective, safe, and natural pesticide technologies for human and
animal health.
TyraTech's products incorporate a unique blend of potent natural
active ingredients and are available in a number of markets
including consumer, commercial, professional pest control,
agriculture, human and animal health, vector control and livestock
markets.
TyraTech, Inc. made its Initial Public Offering in June 2007 on
the AIM section of the London Stock Exchange, where it trades under
the symbol 'TYR'. Since going public, TyraTech has established
partnerships with market leaders in areas such as human health as
well as consumer and commercial pest control operators.
www.tyratech.com
This information is provided by RNS
The company news service from the London Stock Exchange
END
BOANKCDQOBKDFDK
Tyratech (LSE:TYR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Tyratech (LSE:TYR)
Historical Stock Chart
From Jul 2023 to Jul 2024